+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Advantages of the new radiopharmaceutic agent, 99mTC-mercaptoacetyltriglycine (99mTc-MAG3), in the diagnosis of kidneydiseases. A comparative study with 131I-OIH, 99mTc-DTPA and 99mTc-DMSA



Advantages of the new radiopharmaceutic agent, 99mTC-mercaptoacetyltriglycine (99mTc-MAG3), in the diagnosis of kidneydiseases. A comparative study with 131I-OIH, 99mTc-DTPA and 99mTc-DMSA



Bratislavske Lekarske Listy 93(5): 258-265



The properties of 99mTc-mercaptoacetyltriglycine (MAG3), a new radiopharmaceutic for dynamic renal scintigraphy, were assessed in a series of 138 patients with different diseases of the uropoietic system. The physiological values of renographic curves were determined as well as the characteristics of MAG3 excretion, which closely resembled the values for 131I-OIH. On comparing the values of separate MAG3 clearance with standard radiopharmaceutics in 26 subjects examined, very good correlation coefficients (r) were obtained: 0.98, 0.96, and 0.92 for 131I-OIH, 99mTc-DMSA, and 99mTc-DTPA, respectively. Global MAG3 clearance reached 0.64 of the OIH value. The higher quality of scinfigraphic imaging than seen with the substances used so far, the favorable pharmacokinetic properties and the low radiation load (H(E) = 0.51 mSv in adults) of MAG3 determine the indication spheres in which it can best be used to advantage. Of the radiopharmaceutics used to date, MAG3 yields the best results. It can well substitute 123I-OIH, which is not readily available in our conditions, and can thus be expected to be widely used in clinical practice.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039197395

Download citation: RISBibTeXText

PMID: 1327424


Related references

Clinical evaluation of 99mTc-MAG3 renal imaging: comparison with 99mTc-DTPA, 99mTc-DMSA and 131I-OIH. Kaku Igaku. Japanese Journal of Nuclear Medicine 31(2): 131-142, 1994

Renal uptakes of 99mTc-MAG3, 99mTc-DTPA, and 99mTc-DMSA in rabbits with unilateral ureteral obstruction. In Vivo 24(2): 137-139, 2010

Study on tumor affinity of technetium-99m-labeled radiopharmaceuticals. (2) 99mTc-Sn-diphosphonate (99mTc-EHDP), 99mTc-Sn-dimercaptosuccinic acid (99mTc-DMSA), and 99mTc-Sn-diethyl stilbestrol diphosphate (99mTc-DSDP). Radioisotopes 25(10): 622-629, 1976

Comparative evaluation of renoscintigraphic properties and plasma clearance of 99MTc-DADS (99mTc-N,N'-bis/mercaptoacetamido ethylenediamine), 99mTc-DTPA and 131I-o-hippuran. Nuklearmedizin. Nuclear Medicine 22(3): 136-139, 1983

Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA. European Journal of Nuclear Medicine 14(9-10): 453-462, 1988

Will 99mTc-MAG3 replace 131I-OIH and 99mTc-DTPA in the follow-up of renal transplants?. Contributions to Nephrology 79: 118-122, 1990

Physico-chemical study of the radiopharmaceuticals 99mTc-DMSA, 99mTc-EDTA and 99mTc-DTPA interaction with plasmatic proteins. International Journal of Radiation Applications and Instrumentation. Part A Applied Radiation and Isotopes 40(6): 536-538, 1989

P1 Diagnosis Of Pyelonephritic Changes And Renal Scarring By 99Mtc-Mag3 In Comparison To 99Mtc-Dmsa. Nuclear Medicine Communications 26(3): 286-287, 2005

Comparison of relative renal function measured with either 99mTc-DTPA or 99mTc-EC dynamic scintigraphies with that measured with 99mTc-DMSA static scintigraphy. International Braz J Urol 32(4): 405-409, 2006

Phase 3 clinical study of 99mTc-MAG3 injectable, a dynamic renal imaging agent--comparison with 123I-OIH and 99mTc-DTPA. Kaku Igaku. Japanese Journal of Nuclear Medicine 31(2): 183-198, 1994

Comparison of 99mTc-labelled hepatobiliary agents-- 99mTc-pyridoxylidene glutamate (99mTc-PG) and 99mTc-Sn-lidocaine iminodiacetic acid (99mTc-Sn-LIDA). Nuklearmedizin. Nuclear Medicine 15(6): 290-293, 1976

Complexes 99mTc-Sn-DTPA, 99mTc-Fe-ascorbic acid, and 99mTc-Sn-calcium-gluconogalactogluconate in the diagnosis of renal function and morphology. Polski Przeglad Radiologii i Medycyny Nuklearnej 41(1): 57-61, 1977

99mTc-2,3-diaminopropionic acid complex as renal function agent: comparison of biological properties with 99mTc-DTPA and 131I-OIH. International Journal of Radiation Applications and Instrumentation. Part B Nuclear Medicine and Biology 14(6): 599-604, 1987

The 99mTc-Dmsa renal scan and 99mTc-Dtpa diuretic renogram in children and adolescents with incidental diagnosis of horseshoe kidney. Nuclear Medicine Communications 24(5): 525-530, 2003

The 99mTc-DMSA renal scan and 99mTc-DTPA diuretic renogram in children and adolescents with incidental diagnosis of horseshoe kidney. Nuclear Medicine Communications 24(5): 525-530, 2003